Federica Lumetti
A5009797024- Systemic Sclerosis and Related Diseases
- Rheumatoid Arthritis Research and Therapies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Dermatologic Treatments and Research
- Inflammatory Myopathies and Dermatomyositis
- Autoimmune Bullous Skin Diseases
- Mast cells and histamine
- Psoriasis: Treatment and Pathogenesis
- Skin Diseases and Diabetes
- Chronic Lymphocytic Leukemia Research
- Spondyloarthritis Studies and Treatments
- Medical Imaging and Pathology Studies
- Eosinophilic Disorders and Syndromes
- Dermatological and Skeletal Disorders
- Biosimilars and Bioanalytical Methods
- Pulmonary Hypertension Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Radiomics and Machine Learning in Medical Imaging
- Urticaria and Related Conditions
- Pharmaceutical studies and practices
- Dermatological and COVID-19 studies
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Venous Thromboembolism Diagnosis and Management
University of Modena and Reggio Emilia
2016-2025
Azienda Ospedaliero-Universitaria di Modena
2015-2025
University of L'Aquila
2023
Azienda Unita' Sanitaria Locale Di Modena
2023
Weatherford College
2021
Patients First
2021
Scleroderma Foundation
2018
Ospedale di Parma
2014-2016
University of Parma
2015
The persistence in therapy of rheumatoid arthritis drugs and particularly bDMARD is a limiting factor for their long-term use. randomized controlled trials (RCTs) may not reflect real-world contexts due to strict inclusion exclusion criteria. Baricitinib, which targets both JAK1 JAK2, has been used Italy several years. aim this multi-center study assess the real world on baricitinib RA patients identify predictive factors baricitinib's survival rate. This retrospective, multicentric,...
Digital ulcers represent one of the most frequent complications systemic sclerosis (SSc; scleroderma); they are very painful, scarcely responsive to treatment, and often responsible for marked limitations on daily activities, including patient self-care. Infectious may severely compromise outcome skin lesions in a significant percentage patients. Numerous pathogens different origin be involved, bacteria from endogenous flora. Here we evaluated possible involvement fecal scleroderma digital...
The ongoing COVID-19 pandemic caused by the novel β-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a serious challenge for management of patients with different pre-existing comorbidities,1WHOCoronavirus disease 2019 (COVID-19): situation report, 51.https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10Date: March 11, 2020Date accessed: 2020Google Scholar, 2Guan WJ Ni ZY Hu Y et al.Clinical...
Background: Tofacitinib (TOFA) was the first Janus kinase inhibitor (JAKi) to be approved for treatment of rheumatoid arthritis (RA). However, data on retention rate TOFA therapy are still far from definitive. Objective: The goal this study is add new real-world in a cohort RA patients followed long period time. Methods: A multicenter retrospective subjects treated with as monotherapy or combination conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) conducted 23 Italian...
In this multicentre study, we aimed to evaluate the capacity of a computer-assisted automated QCT method identify patients with SSc-associated interstitial lung disease (SSc-ILD) high mortality risk according validated composite clinical indexes (ILD-Gender, Age, Physiology index and du Bois index).Chest CT, anamnestic data pulmonary function tests 146 SSc were retrospectively collected, ILD-Gender, score DuBois calculated. Each chest CT underwent an operator-independent quantitative...
Objective To describe demographic, clinical and laboratory features of systemic sclerosis sine scleroderma (ssSSc) in a large multicentre (SSc) cohort. Methods Data involving 1808 SSc patients from Italian Systemic PRogression INvestiGation registry were collected. The ssSSc was defined by the absence any cutaneous and/or puffy fingers. Clinical serological compared with limited (lcSSc) diffuse (dcSSc) subsets. Results Among SSc, only 61 (3.4%) classified as having (F/M=19/1). Time Raynaud’s...
Objective Bosentan (BOS) is approved for treating pulmonary arterial hypertension (PAH) and preventing digital ulcers (DU) in systemic sclerosis (SSc). Our study aimed to evaluate whether BOS prescribed DU could reduce the incidence of PAH a large SSc cohort from SPRING registry. Methods Patients with registry, meeting ACR/EULAR 2013 classification criteria data on onset, status, exposure, at least one-year follow-up between 2015 2020, no known baseline were included. was diagnosed right...
IXE (Ixekizumab) is a monoclonal antibody targeting interleukin-17A (IL17A) which has demonstrated significant efficacy and safety in the management of psoriatic arthritis (PsA) randomized controlled trials (RCTs). However, available data on long-term persistence therapy are scarce. Methods: This multi-center study aimed to evaluate drug retention rate (DRR) real-world setting identify key factors influencing treatment persistence. 195 patients with PsA treated between 2018 2024 were...
This multicentre study aimed to investigate the overall mortality of combined pulmonary fibrosis and emphysema (CPFE) in systemic sclerosis (SSc) compare CPFE-SSc characteristics with those other SSc subtypes (with interstitial lung disease-ILD, or neither).Chest CTs, anamnestic data, immunological profile function tests patients were retrospectively collected. Each chest CT underwent a semiquantitative assessment blindly performed by three radiologists. Patients clustered four groups:...
Objective There is still a great deal to learn about the influence of sex in systemic sclerosis (SSc). In this respect, national registries provide large and homogeneous patient cohorts for analytical studies. We therefore investigated wide-ranging well-characterized SSc series with aim identifying differences disease expression, special focus on demographic, clinical, serological characteristics. Methods A multicenter cohort 2281 patients, including 247 men, was recruited Italian Systemic...
Interstitial lung disease (ILD) related to systemic sclerosis (SSc) is assessed with pulmonary functional tests (PFTs) and semi-quantitative scores based on extent of ILD detectable chest computed tomography (CT). CT quantitative indexes (QCTIs) are promising tools assess ILD. This study's aim evaluate the validity QCTI compared that standard evaluation PFTs. Moreover, differences between patients' subgroups according prognostic stratifications were investigated.ILD-SSc patients from six...
Objective This study evaluated Neem oil and Hypericum perforatum (Holoil®) for treatment of scleroderma skin ulcers related to calcinosis (SU-calc). Procedure: We retrospectively analyzed 21 consecutive systemic sclerosis (SSc) patients with a total 33 SU-calcs treated daily Holoil® cream compared control group 20 26 SU-calcs. was directly applied lesions, while the received only standard medication. Results Application either resulted in crushing complete resolution calcium deposits or...
Abstract Introduction Interstitial Lung Disease (ILD) is the first cause of death related to Systemic Sclerosis (SSc). The ILD severity can be assessed with clinical, functional and radiological outcome. Nevertheless none them completely validated in clinical practice. Recently a new evaluation based on Quantitative Computed Tomography Indexes (QCTI) was proposed basis voxel‐wise quantitative analysis chest CT. Objectives main aim this study verify if QCTI identify SSc patients significant...
Skin ulcers (SU) represent one of the most frequent manifestations systemic sclerosis (SSc), occurring in almost 50% scleroderma patients. SSc-SU are often particularly difficult to treat with conventional and local therapies. In this study, a preliminary evaluation role effectiveness blue light photobiomodulation (PBM) therapy EmoLED® treatment skin (SSc-SU) was performed.We retrospectively analyzed 12 consecutive SSc patients total 15 SU on finger hands. All were treated adequate for SU;...
The impact of COVID-19 pandemic represents a serious challenge for 'frail' patients' populations with inflammatory autoimmune systemic diseases such as sclerosis (SSc). We investigated the prevalence and severity COVID-19, well effects vaccination campaign in large series SSc patients followed entire period (first 38 months) pandemic.This prospective survey study included 1755 unselected (186 M, 1,569F; mean age 58.7 ± 13.4SD years, disease duration 8.8 7.3SD years) recruited part by...